Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy; Medical Oncology, Azienda Ospedaliera Santa Maria, Terni, Italy.
Department of Oncology, Hematology and Respiratory Diseases, University of Modena and Reggio Emilia, Modena, Italy.
Cancer Treat Rev. 2021 Mar;94:102157. doi: 10.1016/j.ctrv.2021.102157. Epub 2021 Feb 1.
A major breakthrough in cancer immunotherapy was the development of monoclonal antibodies targeting inhibitory immune checkpoint proteins. This approach demonstrated significant antitumor activity and efficacy in different cancer types, including metastatic renal cell carcinoma (mRCC). In the majority of patients, this drug is able to restore the patient's tumour-specific T-cell-mediated response thus improving both overall survival and objective response rate. However, a lack of clinical response occurs in a number of patients, raising questions about how to predict and increase the number of patients who receive long-term clinical benefit from immune checkpoint therapy or not. The aim of this review is to summarize available data about immune biomarkers in patients with mRCC treated with immunotherapy.
癌症免疫疗法的一个重大突破是开发针对抑制性免疫检查点蛋白的单克隆抗体。这种方法在不同类型的癌症中表现出显著的抗肿瘤活性和疗效，包括转移性肾细胞癌（mRCC）。在大多数患者中，该药物能够恢复患者的肿瘤特异性 T 细胞介导的反应，从而提高总生存率和客观缓解率。然而，许多患者缺乏临床反应，这引发了关于如何预测和增加接受免疫检查点治疗的患者获得长期临床获益的人数的问题。本综述的目的是总结关于接受免疫治疗的 mRCC 患者的免疫生物标志物的现有数据。
